Our Science

We are building a product pipeline for rapid control of existing and emerging infectious diseases.

​

Ongoing studies for additional TPOXX indications

 

Post-exposure prophylaxis

 

Post-exposure prophylaxis (PEP) holds immense potential medical benefit, particularly within immunocompromised patient populations. It offers a crucial line of defense against infectious diseases following potential exposure and prior to display of symptoms, thereby safeguarding vulnerable individuals from severe complications. TPOXX is currently being evaluated for PEP treatment in adults exposed to smallpox. This program is funded and supported in collaboration with the U.S. Department of Defense.

 

Mpox

 

Mpox has been seen as an emerging issue and threat to global health since 2016, with recent global outbreaks occurring in 2022. While available vaccines can be effective at preventing mpox, protection is neither complete nor durable, leaving patients vulnerable to disease progression and transmission. Since the 2022 outbreak, TPOXX has been recommended by the CDC for treatment, off-label, following a formal diagnosis or suspected case of mpox, and it is currently being evaluated for the treatment of mpox in randomized clinical trials (STOMP trial). For more information on the STOMP trial and eligibility, see here.

 

Note: Tecovirimat-SIGA is approved by the EMA and MHRA for the treatment of smallpox, mpox, cowpox, and vaccinia complications following vaccination against smallpox in adults and children weighing at least 13kg. Tecovirimat is not yet approved as a treatment for mpox outside of the EU and UK.

​

Liquid suspension pediatric formulation

​

A smallpox outbreak affecting children needs a therapy to reduce severe illness and death. An oral liquid suspension pediatric formulation of TPOXX is currently being investigated for the treatment of smallpox in patients weighing less than 13kg. This program is funded and supported in collaboration with Biomedical Advanced Research and Development Authority (BARDA).